Share this post on:

Product Name :
Darifenacin Hydrobromide

Search keywords :
Darifenacin (hydrobromide)

drugId :
null

Target Vo:
Muscarinic acetylcholine receptor M3

Target Vo Short Name :
CHRM3

Moa_Name:
Muscarinic acetylcholine receptor M3 antagonists

First Approval Country :
EU

First Approval Date Filter:
2004

Origin Company_Name :
Novartis Pharma Ag

Active Company_Name :
Abbvie Inc

Active Indication_Name:
Urinary Bladder, Overactive

In Active Indication_Name:
Multiple Sclerosis

Termination Status :

China Termination Status :

Highest Status:
Approved

China Highest Status:
Phase 1 Clinical

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
CD44 Antibody
HER2 Antibody (YA771)
MTNR1B Antibody: MTNR1B Antibody is an unconjugated, approximately 40 kDa, rabbit-derived, anti-MTNR1B polyclonal antibody. MTNR1B Antibody can be used for: WB, ELISA, IHC-P, IHC-F, IF expriments in human, mouse, rat, and predicted: dog background without labeling.

Share this post on:

Author: Interleukin Related